It behaves in perfectly rational and understandable ways that correspond directly with the way it's incentivized. Developing new drugs is expensive, getting them approved is more expensive, and there's no guarantee it will work or be approved.

As a corporate entity, drug companies are capable of deploying investors' capital in a variety of ways. If they neglected the ways that actually made money, they would be short on investors pretty quickly.